Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 6/20 | 0.69 |
| ▸ | RAB9A | P51151 | 5/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.69 |
| ▸ | CA12 | O43570 | 4/20 | 0.69 |
| ▸ | CA2 | P00918 | 4/20 | 0.69 |
| ▸ | CA9 | Q16790 | 4/20 | 0.69 |
| ▸ | MEN1 | O00255 | 4/20 | 0.69 |
| ▸ | POLB | P06746 | 2/20 | 0.69 |
| ▸ | F2 | P00734 | 3/20 | 0.59 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.59 |
| ▸ | PRSS2 | P07478 | 3/20 | 0.59 |
| ▸ | PRSS3 | P35030 | 3/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.59 |
| ▸ | TSHR | P16473 | 3/20 | 0.59 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL42343 | 1.00 | NPC1 (0.69) | NPC1RAB9AKMT2ACA12CA2 | |
| SCHEMBL295564 | 0.88 | ALDH1A1 (0.61) | NPC1RAB9AKMT2ACA12CA2 | |
| SCHEMBL29592346 | 0.86 | NPC1 (0.65) | NPC1RAB9AKMT2ACA12CA2 | |
| SCHEMBL15631068 | 0.85 | NPC1 (0.73) | NPC1RAB9AKMT2ACA12CA2 | |
| SCHEMBL9620534 | 0.84 | HSD17B10 (0.52) | NPC1RAB9AKMT2ACA12CA2 | |
| SCHEMBL9019288 | 0.83 | NPC1 (0.71) | NPC1RAB9AKMT2ACA12CA2 | |
| SCHEMBL13602555 | 0.83 | NPC1 (0.71) | NPC1RAB9AKMT2ACA12CA2 | |
| SCHEMBL13384871 | 0.83 | NPC1 (0.71) | NPC1RAB9AKMT2ACA12CA2 | |
| SCHEMBL14419936 | 0.83 | NPC1 (0.71) | NPC1RAB9AKMT2ACA12CA2 | |
| Methyl Orange SCHEMBL18892 | 0.81 | KMT2A (0.69) | NPC1RAB9AKMT2ACA12CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 779 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260092921-A1 | MUTATED NEUROAMINIDASE | ROCHE DIAGNOSTICS GMBH (DE) | 2026-04-02 | — | — | US | claimed |
| CN-119044389-A | Method for detecting theanine and gamma-aminobutyric acid by pre-column derivatization of DABS-Cl | 徐敦明 | 2024-11-29 | — | — | CN | claimed |
| CN-118090992-A | Method for detecting content of gamma-aminobutyric acid in wine | 宜宾五粮液股份有限公司 | 2024-05-28 | — | — | CN | claimed |
| WO-2024020584-A2 | GRAYSCALE FABRICATION OF 4D MATERIALS | UNIVERSITY OF WASHINGTON (US) | 2024-01-25 | — | — | WO | claimed |
| CN-114081185-A | Gamma-aminobutyric acid detection method and composition for improving sleep and resisting anxiety | 程新 | 2022-02-25 | — | — | CN | claimed |
| US-20180267067-A1 | METHODS FOR BIOANALYSIS OF 6-DIAZO-5-OXO-L-NORLEUCINE (DON) AND OTHER GLUTAMINE ANTAGONISTS | THE JOHNS HOPKINS UNIVERSITY (US) | 2018-09-20 | — | — | US | claimed |
| EP-3245296-A1 | IN VITRO METHOD FOR ESTIMATING IN VIVO PROTEIN DIGESTIBILITY | General Mills, Inc. (US) | 2017-11-22 | — | — | EP | claimed |
| US-9738920-B2 | In vitro method for estimating in vivo protein digestibility | GENERAL MILLS, INC. (US) | 2017-08-22 | — | — | US | claimed |
| US-9715998-B2 | Method for monitoring level of paraben in cosmetics | Kaohsuing Medical University (TW) | 2017-07-25 | — | — | US | claimed |
| US-20160208309-A1 | IN VITRO METHOD FOR ESTIMATING IN VIVO PROTEIN DIGESTIBILITY | GENERAL MILLS, INC. | 2016-07-21 | — | — | US | claimed |
| US-6251680-B1 | REACTING POLYMER WITH AMINE | ROHM AND HAAS COMPANY | 2001-06-26 | — | — | US | claimed |
| WO-2001009610-A1 | METHOD TO MEASURE ACYL-COENZYME A ESTERS | THE UNIVERSITY COURT OF THE UNIVERSITY OF GLASGOW (GB) | 2001-02-08 | — | — | WO | claimed |
| WO-2000067022-A2 | LABORATORY EXAMINATION OF A BODY FLUID OR TISSUE SAMPLE | HOERRMANN WILHELM (DE) | 2000-11-09 | — | — | WO | claimed |
| EP-0606925-B1 | A method for derivatizing a 1-amino-1-deoxyoligosaccharide | GENZYME CORP (US) | 1998-10-07 | — | — | EP | claimed |
| EP-0785422-A1 | Detectable polymers and methods for detecting polymers in aqueous systems | ROHM AND HAAS COMPANY (US) | 1997-07-23 | — | — | EP | claimed |
| EP-0389437-B1 | Luciferin derivatives | NIPPON ZOKI PHARMACEUTICAL CO (JP) | 1995-05-24 | — | — | EP | claimed |
| US-5283353-A | Enzymeric cleavage from glycoprotein | GENZYME CORPORATION (US) | 1994-02-01 | — | — | US | claimed |
| EP-0389437-A1 | Luciferin derivatives | NIPPON ZOKI PHARMACEUTICAL CO. LTD. (JP) | 1990-09-26 | — | — | EP | claimed |
| WO-1989008835-A1 | THIOACYLATION PEPTIDE SEQUENCING WITH ACYLATION OF THIAZOLINES | BIO-AFFINITY SYSTEMS, INC. (US) | 1989-09-21 | — | — | WO | claimed |
| US-4861726-A | Method of thioacylation peptide sequencing with acylation of thiazoloinones | BIO-AFFINITY SYSTEMS, INC. (US) | 1989-08-29 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180267067-A1 | METHODS FOR BIOANALYSIS OF 6-DIAZO-5-OXO-L-NORLEUCINE (DON) AND OTHER GLUTAMINE ANTAGONISTS | GLUL, GLS, ASNS | NPC1 2495/4885RAB9A 2269/4885KMT2A 3039/4885 |
| US-20260092921-A1 | MUTATED NEUROAMINIDASE | NEU4, HEXB, NEU2 | NPC1 1443/4885RAB9A 3191/4885KMT2A 126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.